Kite Pharma Europe Expanding in Amsterdam
An agreement with the Netherlands Cancer Institute (NKI) will increase collaboration
California-based Kite Pharma, Inc. is expanding its European headquarters, located in Amsterdam, by increasing collaboration with the Netherlands Cancer Institute (NKI). The clinical-stage biopharmaceutical company will have increased access to resources and research facilities through the agreement with the NKI. In addition, Kite will receive the exclusive option to license multiple gene sequences for the development and commercialization of cancer immunotherapy.
“With Kite Pharma EU, we have established a central hub of cancer immunotherapy efforts in Europe, attracting leading scientific experts, researchers and collaborators in this field,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. “Kite’s relationship with the NKI, an internationally renowned cancer research and clinical institution, provides an important operational platform.”
Professor René Medema, Director of NKI added, “We are excited with the progress of the TCR research programs with Kite. NKI believes that TCR technologies hold great potential for cancer care and we are committed to making these new therapies a reality for patients.”
Source: Kite Pharma14 September 2015